These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36368749)

  • 1. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial.
    Morath C; Schmitt A; Schmitt M; Wang L; Kleist C; Opelz G; Süsal C; Tran TH; Scherer S; Schwenger V; Kemmner S; Fischereder M; Stangl M; Hauser IA; Sommerer C; Nusshag C; Kälble F; Speer C; Benning L; Bischofs C; Sauer S; Schubert ML; Kunz A; Hückelhoven-Krauss A; Neuber B; Mehrabi A; Schwab C; Waldherr R; Sander A; Büsch C; Czock D; Böhmig GA; Reiser J; Roers A; Müller-Tidow C; Terness P; Zeier M; Daniel V; Schaier M
    BMJ Open; 2022 Nov; 12(11):e066128. PubMed ID: 36368749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.
    Brook MO; Hester J; Petchey W; Rombach I; Dutton S; Bottomley MJ; Black J; Abdul-Wahab S; Bushell A; Lombardi G; Wood K; Friend P; Harden P; Issa F
    BMJ Open; 2022 Apr; 12(4):e061864. PubMed ID: 35428650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients.
    Morath C; Schaier M; Ibrahim E; Wang L; Kleist C; Opelz G; Süsal C; Ponath G; Aly M; Alvarez CM; Kälble F; Speer C; Benning L; Nusshag C; Pego da Silva L; Sommerer C; Hückelhoven-Krauss A; Czock D; Mehrabi A; Schwab C; Waldherr R; Schnitzler P; Merle U; Tran TH; Scherer S; Böhmig GA; Müller-Tidow C; Reiser J; Zeier M; Schmitt M; Terness P; Schmitt A; Daniel V
    J Am Soc Nephrol; 2023 Jan; 34(1):160-174. PubMed ID: 36137752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT.
    Haupenthal F; Rahn J; Maggi F; Gelas F; Bourgeois P; Hugo C; Jilma B; Böhmig GA; Herkner H; Wolzt M; Doberer K; Vossen M; Focosi D; Neuwirt H; Banas M; Banas B; Budde K; Viklicky O; Malvezzi P; Rostaing L; Rotmans JI; Bakker SJL; Eller K; Cejka D; Pérez AM; Rodriguez-Arias D; König F; Bond G;
    Trials; 2023 Mar; 24(1):213. PubMed ID: 36949445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients.
    Ho J; Sharma A; Kroeker K; Carroll R; De Serres S; Gibson IW; Hirt-Minkowski P; Jevnikar A; Kim SJ; Knoll G; Rush DN; Wiebe C; Nickerson P
    BMJ Open; 2019 Apr; 9(4):e024908. PubMed ID: 30975673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
    Schaier M; Morath C; Wang L; Kleist C; Opelz G; Tran TH; Scherer S; Pham L; Ekpoom N; Süsal C; Ponath G; Kälble F; Speer C; Benning L; Nusshag C; Mahler CF; Pego da Silva L; Sommerer C; Hückelhoven-Krauss A; Czock D; Mehrabi A; Schwab C; Waldherr R; Schnitzler P; Merle U; Schwenger V; Krautter M; Kemmner S; Fischereder M; Stangl M; Hauser IA; Kälsch AI; Krämer BK; Böhmig GA; Müller-Tidow C; Reiser J; Zeier M; Schmitt M; Terness P; Schmitt A; Daniel V
    Front Immunol; 2023; 14():1089664. PubMed ID: 37483623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised controlled trial of a video intervention and behaviour contract to improve medication adherence after renal transplantation: the VECTOR study protocol.
    Mansell H; Rosaasen N; West-Thielke P; Wichart J; Daley C; Mainra R; Shoker A; Liu J; Blackburn D
    BMJ Open; 2019 Mar; 9(3):e025495. PubMed ID: 30872550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
    Sawitzki B; Harden PN; Reinke P; Moreau A; Hutchinson JA; Game DS; Tang Q; Guinan EC; Battaglia M; Burlingham WJ; Roberts ISD; Streitz M; Josien R; Böger CA; Scottà C; Markmann JF; Hester JL; Juerchott K; Braudeau C; James B; Contreras-Ruiz L; van der Net JB; Bergler T; Caldara R; Petchey W; Edinger M; Dupas N; Kapinsky M; Mutzbauer I; Otto NM; Öllinger R; Hernandez-Fuentes MP; Issa F; Ahrens N; Meyenberg C; Karitzky S; Kunzendorf U; Knechtle SJ; Grinyó J; Morris PJ; Brent L; Bushell A; Turka LA; Bluestone JA; Lechler RI; Schlitt HJ; Cuturi MC; Schlickeiser S; Friend PJ; Miloud T; Scheffold A; Secchi A; Crisalli K; Kang SM; Hilton R; Banas B; Blancho G; Volk HD; Lombardi G; Wood KJ; Geissler EK
    Lancet; 2020 May; 395(10237):1627-1639. PubMed ID: 32446407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre randomised controlled trial: protocol for Plasma-Lyte Usage and Assessment of Kidney Transplant Outcomes in Children (PLUTO).
    Hayes W; Laing E; Foley C; Pankhurst L; Thomas H; Hume-Smith H; Marks S; Kessaris N; Bryant WA; Spiridou A; Wray J; Peters MJ
    BMJ Open; 2022 Mar; 12(3):e055595. PubMed ID: 35288387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial.
    Maláska J; Stašek J; Duška F; Balík M; Máca J; Hruda J; Vymazal T; Klementová O; Zatloukal J; Gabrhelík T; Novotný P; Demlová R; Kubátová J; Vinklerová J; Svobodník A; Kratochvíl M; Klučka J; Gál R; Singer M;
    Trials; 2021 Mar; 22(1):172. PubMed ID: 33648568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of donor-derived modified immune cell infusion in kidney transplantation.
    Morath C; Schmitt A; Kleist C; Daniel V; Opelz G; Süsal C; Ibrahim E; Kälble F; Speer C; Nusshag C; Pego da Silva L; Sommerer C; Wang L; Ni M; Hückelhoven-Krauss A; Czock D; Merle U; Mehrabi A; Sander A; Hackbusch M; Eckert C; Waldherr R; Schnitzler P; Müller-Tidow C; Hoheisel JD; Mustafa SA; Alhamdani MS; Bauer AS; Reiser J; Zeier M; Schmitt M; Schaier M; Terness P
    J Clin Invest; 2020 May; 130(5):2364-2376. PubMed ID: 31990685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial.
    Roemhild A; Otto NM; Moll G; Abou-El-Enein M; Kaiser D; Bold G; Schachtner T; Choi M; Oellinger R; Landwehr-Kenzel S; Juerchott K; Sawitzki B; Giesler C; Sefrin A; Beier C; Wagner DL; Schlickeiser S; Streitz M; Schmueck-Henneresse M; Amini L; Stervbo U; Babel N; Volk HD; Reinke P
    BMJ; 2020 Oct; 371():m3734. PubMed ID: 33087345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
    Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
    Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.
    Harden PN; Game DS; Sawitzki B; Van der Net JB; Hester J; Bushell A; Issa F; Brook MO; Alzhrani A; Schlickeiser S; Scotta C; Petchey W; Streitz M; Blancho G; Tang Q; Markmann J; Lechler RI; Roberts ISD; Friend PJ; Hilton R; Geissler EK; Wood KJ; Lombardi G
    Am J Transplant; 2021 Apr; 21(4):1603-1611. PubMed ID: 33171020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.